Skip to content
38

bifonazol creme

Skip it

Brand-locked demand (top 5 brands take 100% of clicks) — this niche doesn't clear our bar today.

Market size 17Growth 32Conversion 96Competition 7Returns 100Price range 18Avg price 28Brand share 0Review moat 61Quality gap 40

Returns

Incredible0.0%

return rate — above 6% kills the launch gate

Conversion

Incredible14.2%

search→purchase rate — share of searches ending in a sale

Review moat

Good1,046.57

avg incumbent reviews — the moat a new listing must climb

Quality gap

Okay4.5★

avg incumbent rating — lower means beatable quality

Growth

Okay+5.7%

90-day search growth — must beat 0% to launch

Avg price

Okay€9.39

avg listing price — sweet spot $15–$100

Price range

Bad€5.54–€17.14

cheapest to priciest tracked listing — scored on the share inside $15–$100

Market size

Bad€70K

€70K/yr · 52K searches

Competition

Bad92%

top-5 click share — a locked-up shelf

Brand share

Bad100%

top-5 brand share — brand-locked demand

Competition

The top 5 products capture 92% of clicks — a locked-up shelf that new listings rarely crack.

Brands

4 falling

Sellers

23

Top-5 brand share

100%

Open market

0%

  • Bifon56%
  • Aristo17%
  • Dermapharm AG Arzneimittel14%
  • Canesten13%

Product shelf

Each bubble is one product — market share against review moat; bubble size tracks estimated sales, color grades how beatable the incumbent looks.

0%15%€10K30%€21K45%€31K60%€42K101001K10K Reviews — right = deep review moat Market share (90d) ≈ est. sales
Beatable (≤4.3★) Contested Strong incumbent (>4.7★)

All 7 tracked products in this niche — three views at once, no toggling.

Demand

Weekly Amazon search volume, last 49 weeks — +5.7% search growth over the last 90 days.
1K750Spike '26Aug '25Sep '25Nov '25Jan '26Mar '26May '26

Reviews

What buyers praise and complain about, mined from review topics.

What buyers complain about

Hartes Gefühl50%

“Das Gel ist extrem hart”

Allergien25%

“der Juckreiz war zum Teil unerträglich.”

Nebenwirkungen25%

“Die letzte Hoffnung war dann das hochgelobte Terbinafin - leider ebenfalls ohne Wirkung”